Company: DAWN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026654
Chunk: 290

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1B
Chunk 290
---
,241

    Deferred revenue

    4,787

    —

    —

    Operating lease liability

    (273
    )

    (405
    )

    (347
    )

    Other long-term liability

    761

    —

    —

    Net cash used in operating activities

    (78,113
    )

    (146,853
    )

    (109,874
    )

    Cash flows from investing activities:

    Cash paid for purchase of short-term investments

    (658,616
    )

    (443,838
    )

    (394,206
    )

    Proceeds from maturity of short-term investments

    314,482

    575,440

    139,158

    Proceeds from sale of short-term investments

    79,409

    —

    —

    Cash paid for acquired intangible assets

    (17,100
    )

    —

    —

    Proceeds from sale of priority review voucher

    108,000

    —

    —

    Cash paid for acquired in-process research and development assets

    (55,000
    )

    (3,000
    )

    —

    Cash paid for purchase of property and equipment

    (2,169
    )

    (224
    )

    (26
    )

    Net cash (used in) provided by investing activities

    (230,994
    )

    128,378

    (255,074
    )

    Cash flows from financing activities:

    Proceeds from issuance of common stock in connection with private placement, net of placement agent fees and offering costs

    178,177

    —

    —

    Proceeds from issuance of prefunded warrants to purchase common stock in connection with private placement, net of issuance costs

    20,941

    —

    —

    Proceeds from issuance of common stock, net

    —

    161,409

    161,610

    Proceeds from issuance of common stock upon stock option exercises

    2,267

    1,338

    3,649

    Proceeds from issuance of common stock upon Employee Stock Purchase Plan purchase

    1,906

    1,250

    642

    Cash provided by financing activities

    203,291

    163,997

    165,901

    Net (decrease) increase in cash and cash equivalents

    (105